Systemic Lupus Erythematous SLE Drugs Market Segments and Forecast By End-use Industry 2015-2025
Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering. Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering.
Report Description Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market. Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1149 Systemic Lupus Erythematous (SLE) Drugs Market: Segmentation The global systemic lupus erythematous drugs market is classified on the basis of molecule and region. Based on type of molecule, the global systemic lupus erythematous drugs market is segmented into the following: Corticosteroids Prednisone Cortisone Hydrocortisone
Report Description •Non-Steroidal Anti-inflammatory Drugs (NSAIDs) • Over-the-counter NSAIDs include • Ibuprofen (Motrin) • Naproxen (Naprosyn) • Prescription versions include • Indomethacin (Indocin) • Nabumetone (RELAFEN) • Celecoxib (Celebrex) •Anti-Inflammatories • Aspirin • Acetaminophen (Tylenol) •Disease-Modifying Anti-Rheumatic Drugs (DMARDs) • Hydroxychloroquine (Plaquenil). • Cyclosporine (Gengraf, Neoral, Sandimmune) • Azathioprine (Azasan, Imuran) •Antimalarials • Chloroquine (Aralen) • Hydroxychloroquine (Plaquenil)
- Page 1 and 2: Global Systemic Lupus Erythematous
- Page 3: Report Description Systemic Lupus E
- Page 7 and 8: Report Description Recently, a drug
Report Description<br />
•Non-Steroidal Anti-inflammatory <strong>Drugs</strong> (NSAIDs)<br />
• Over-the-counter NSAIDs include<br />
• Ibuprofen (Motrin)<br />
• Naproxen (Naprosyn)<br />
• Prescription versions include<br />
• Indomethacin (Indocin)<br />
• Nabumetone (RELAFEN)<br />
• Celecoxib (Celebrex)<br />
•Anti-Inflammatories<br />
• Aspirin<br />
• Acetaminophen (Tylenol)<br />
•Disease-Modifying Anti-Rheumatic <strong>Drugs</strong> (DMARDs)<br />
• Hydroxychloroquine (Plaquenil).<br />
• Cyclosporine (Gengraf, Neoral, S<strong>and</strong>immune)<br />
• Azathioprine (Azasan, Imuran)<br />
•Antimalarials<br />
• Chloroquine (Aralen)<br />
• Hydroxychloroquine (Plaquenil)
Change language